Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Share:
Related AZN
How Altimmune Is Trying To Get Ahead Of A Potential 'Flu Pandemic'
Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma

Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.

Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."

AstraZeneca closed at $45.80 on Thursday.

Latest Ratings for AZN

DateFirmActionFromTo
May 2017Credit SuisseUpgradesUnderperformNeutral
Dec 2016Leerink SwannUpgradesMarket PerformOutperform
Sep 2016PiperJaffrayInitiates Coverage onOverweight

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: SwedbankAnalyst Color Downgrades Analyst Ratings

 

Related Articles (AZN)

View Comments and Join the Discussion!